Advertisement
All shareholders of record at the close of business on July 13, 2009 willbe entitled to attend and vote at the Meeting, and at any adjournment orpostponement thereof, or to appoint a proxy to attend and vote in his/herplace. The proxy need not be a shareholder of the Company.
Advertisement
This notice and other information with regards to the Meeting areavailable on the investor relation section of the Company's website:http://www.simcere.com .
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR; Simcere) is a leadingmanufacturer and supplier of branded generic and innovative pharmaceuticals inChina. In recent years, Simcere has been focusing its strategy on thedevelopment of innovative pharmaceuticals and first-to-market generics, andhas introduced an innovative anti-cancer medication Endu, a first-to-marketmedication Sinofuan, and first-to-market generics such as Bicun and Anxin.Simcere manufactures and sells antibiotics, anti-cancer medication and strokemanagement medication. Simcere concentrates its research and developmentefforts on the treatment of diseases with high incidence and/or mortalityrates and for which there is a clear demand for more effective pharmacotherapysuch as cancer, strokes, orthopaedics and infectious diseases. For moreinformation about Simcere Pharmaceutical Group, please visithttp://www.simcere.com .The meeting is being held for the following purposes: 1. To receive a report on the Company's operation. 2. To transact any other business properly brought before the Meeting.
SOURCE Simcere Pharmaceutical Group